CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer
CERo Therapeutics has announced key appointments to its management team. Andrew Albert 'Al' Kucharchuk has been named Chief Financial Officer and Kristen Pierce, Ph.D., has been appointed Chief Development Officer. These appointments support interim CEO Chris Ehrlich in advancing CERo's mission to develop next-generation T cell therapeutics. Mr. Kucharchuk brings extensive experience from roles at Nukkelous, Chain Bridge I, Theralink, Adhera Therapeutics, and OncBioMune. Dr. Pierce has over 20 years of oncology experience, previously holding leadership roles at Pionyr Therapeutics and Pfizer Therapeutics. The team aims to drive CERo's lead compound, CER-1236, through ongoing in vitro studies towards a successful Type A meeting with the FDA.
CERo Therapeutics ha annunciato importanti nomine nel suo team di gestione. Andrew Albert 'Al' Kucharchuk è stato nominato Chief Financial Officer e Kristen Pierce, Ph.D., è stata designata Chief Development Officer. Queste nomine supportano il CEO ad interim Chris Ehrlich nel portare avanti la missione di CERo di sviluppare terapie per i linfociti T di nuova generazione. Il Sig. Kucharchuk porta con sé una vasta esperienza da ruoli ricoperti in Nukkelous, Chain Bridge I, Theralink, Adhera Therapeutics e OncBioMune. La Dott.ssa Pierce ha oltre 20 anni di esperienza nel settore oncologico, avendo ricoperto in precedenza ruoli di leadership in Pionyr Therapeutics e Pfizer Therapeutics. Il team mira a guidare il composto principale di CERo, CER-1236, attraverso studi in vitro in corso verso un incontro di successo di Tipo A con la FDA.
CERo Therapeutics ha anunciado nombramientos clave en su equipo de gestión. Andrew Albert 'Al' Kucharchuk ha sido nombrado Director Financiero y Kristen Pierce, Ph.D., ha sido designada Directora de Desarrollo. Estos nombramientos apoyan al CEO interino Chris Ehrlich en avanzar con la misión de CERo de desarrollar terapias de células T de nueva generación. El Sr. Kucharchuk aporta una amplia experiencia de roles en Nukkelous, Chain Bridge I, Theralink, Adhera Therapeutics y OncBioMune. La Dra. Pierce cuenta con más de 20 años de experiencia en oncología, habiendo ocupado anteriormente puestos de liderazgo en Pionyr Therapeutics y Pfizer Therapeutics. El equipo busca impulsar el compuesto principal de CERo, CER-1236, a través de estudios in vitro en curso hacia una reunión exitosa de Tipo A con la FDA.
CERo Therapeutics는 경영 팀의 주요 임명 사항을 발표했습니다. Andrew Albert 'Al' Kucharchuk는 최고 재무 책임자(Chief Financial Officer)로, Kristen Pierce, Ph.D.는 최고 개발 책임자(Chief Development Officer)로 임명되었습니다. 이러한 임명은 임시 CEO인 Chris Ehrlich가 CERo의 신세대 T세포 치료제 개발 임무를 추진하는 데 도움을 줍니다. Kucharchuk 씨는 Nukkelous, Chain Bridge I, Theralink, Adhera Therapeutics 및 OncBioMune에서의 경력을 통해 광범위한 경험을 제공합니다. Pierce 박사는 온콜로지 분야에서 20년 이상의 경력을 가지고 있으며, 이전에 Pionyr Therapeutics 및 Pfizer Therapeutics에서 리더십 역할을 수행했습니다. 이 팀은 CERo의 주요 화합물인 CER-1236을 새로운 임상 시험에 성공적으로 진입시키기 위해 진행 중인 시험 연구를 통해 추진할 계획입니다.
CERo Therapeutics a annoncé des nominations clés au sein de son équipe de direction. Andrew Albert 'Al' Kucharchuk a été nommé directeur financier et Kristen Pierce, Ph.D. a été désignée directrice du développement. Ces nominations soutiennent le directeur général par intérim Chris Ehrlich dans l'avancement de la mission de CERo, qui consiste à développer des thérapies T-cellulaires de nouvelle génération. M. Kucharchuk apporte une vaste expérience acquise dans des rôles chez Nukkelous, Chain Bridge I, Theralink, Adhera Therapeutics et OncBioMune. Dr. Pierce possède plus de 20 ans d'expérience en oncologie, ayant précédemment occupé des postes de direction chez Pionyr Therapeutics et Pfizer Therapeutics. L'équipe vise à faire progresser le composé phare de CERo, CER-1236, à travers des études in vitro en cours en vue d'une réunion réussie de type A avec la FDA.
CERo Therapeutics hat wichtige Ernennungen in seinem Management-Team bekannt gegeben. Andrew Albert 'Al' Kucharchuk wurde zum Chief Financial Officer ernannt und Kristen Pierce, Ph.D. wurde zur Chief Development Officer ernannt. Diese Ernennungen unterstützen den amtierenden CEO Chris Ehrlich bei der Weiterverfolgung der Mission von CERo, Therapeutika der nächsten Generation für T-Zellen zu entwickeln. Herr Kucharchuk bringt umfangreiche Erfahrung aus seiner Tätigkeit bei Nukkelous, Chain Bridge I, Theralink, Adhera Therapeutics und OncBioMune mit. Dr. Pierce hat über 20 Jahre Erfahrung in der Onkologie und hat zuvor Führungspositionen bei Pionyr Therapeutics und Pfizer Therapeutics innegehabt. Das Team hat sich zum Ziel gesetzt, die Hauptverbindung von CERo, CER-1236, durch laufende In-vitro-Studien in Richtung eines erfolgreichen Typ-A-Meetings mit der FDA voranzutreiben.
- Key appointments of experienced professionals to critical roles.
- Focus on advancing CER-1236 through clinical development.
- None.
SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces key appointments to the Company’s management team to support recently named interim CEO, Chris Ehrlich. Andrew Albert “Al” Kucharchuk has been named Chief Financial Officer and Kristen Pierce, Ph.D., has been appointed Chief Development Officer.
“I believe we have the team in place to successfully drive CERo forward into the clinic and to create the Company we have promised our shareholders. These new management team members are seasoned professionals with extensive experience in early drug development and the capital markets. I want to take this opportunity to thank Brian Atwood for his service as CEO, and appreciate his continued service on our Board of Directors. Further, I am very excited to begin to collaborate closely with Al and Kristen to help us achieve our ambitious goals,” said Mr. Ehrlich. “The science behind CER-1236 is very promising and our team is fully dedicated to stewarding both the compound and the Company into 2025 and beyond. We look forward to completing the ongoing in vitro studies and experiments to enable a successful Type A meeting with the FDA.”
Mr. Kucharchuk joins CERo from Nukkelous, Inc. and Chain Bridge I, Inc., both Nasdaq-traded companies where he served as Chief Financial Officer. Previously, he served in C-suite positions and/or as a board member at publicly traded life sciences companies Theralink (CFO, Board member), Adhera Therapeutics (Board member, multiple C-suite positions), and OncBioMune (CEO, CFO, President). He holds a Master of Business Administration from Tulane University and a Bachelor of Science degree in agricultural business/finance from Louisiana State University.
Kristen Pierce, Ph.D. has over 20 years of oncology experience, leading nonclinical and early clinical stage projects. Prior to joining CERo, Kristen was Vice President, Translational Medicine at Pionyr Therapeutics. Prior, she served as Executive Director, Asset Team Leader at Pfizer Therapeutics where she led the late nonclinical and early clinical development of several antibody and small molecules in oncology. Dr. Pierce received her Ph.D. from the University of Arizona in Pharmacology and Toxicology and spent four years as a postdoc at Duke University in the laboratory of the Nobel Prize winning scientist, Dr. Robert J. Lefkowitz.
About CERo Therapeutics, Inc.
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (“CER-T”). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor (“CAR-T”) cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2024 for hematological malignancies.
Forward-Looking Statements
This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo’s management.
Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 2, 2024, and the documents incorporated by reference therein. The risks described in CERo’s filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Brian Atwood
Chief Executive Officer
batwood@cero.bio
Investors:
CORE IR
investors@cero.bio
FAQ
Who is the new CFO of CERo Therapeutics as of October 2024?
Who is the new Chief Development Officer of CERo Therapeutics?
What is the significance of the new appointments at CERo Therapeutics?
What experience does the new CFO of CERo Therapeutics bring?
What is Dr. Kristen Pierce's background before joining CERo Therapeutics?
What is the lead compound that CERo Therapeutics is focusing on?
